Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page
- Check3 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference1.0%
- Check10 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1%
- Check17 days agoChange DetectedThe page has removed a reference to a study on the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer.SummaryDifference0.6%
- Check24 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.9%
- Check31 days agoNo Change Detected
- Check38 days agoChange DetectedThe web page has been updated to include new information regarding the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer, along with a revision update from v2.16.1 to v2.16.2.SummaryDifference0.7%
- Check46 days agoChange DetectedThe page has been updated to include information about the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, and it now features new references related to pembrolizumab and a randomized trial for non-small-cell lung cancer. Additionally, an older reference has been removed.SummaryDifference8%
Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.